XOMA Corporation (XOMA) Disappoints

XOMA Corporation (XOMA) shares are down $0.04 to $3.68 in after-hours trading Wednesday after the company reported its fourth quarter 2014 earnings results.

The drug developer reported earnings of ($0.12) per share on revenues of $4.3 million, down 65.6% from a year ago. Analysts were expecting EPS of ($0.09) on revenues of $11.17 million.

For the year ended Dec. 31, 2014, the company reported that its loss narrowed to $38.3 million from $124.1 million in 2013. Revenue was reported as $18.9 million, compared with $35.5 million in 213.

On valuation measures, XOMA Corp. shares, which currently have an average 3-month trading volume of 2.58 million shares, trade at a P/E to growth ratio of (0.4). The median Wall Street price target on the name is $9.00 with a high target of $17.00. Currently ticker boasts 7 ‘Buy’ endorsements, compared to 2 ’Holds’ and no ‘Sell’.

Profitability-wise, XOMA has a t-12 operating margin of (288.63%). The $399.51 million market cap company reported $78.4 million in cash in its most recent quarter.

XOMA currently prints a one year loss of 36.63% and a year-to-date return of 3.62%.

The chart below shows where the equity has traded over the last 52 weeks.

XOMA Corp. discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company was founded in 1981 and is headquartered in Berkeley, California.

Be the first to comment

Leave a Reply

Your email address will not be published.


*